Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Atorvastatin and simvastatin decrease the uptake of acetylated low-density lipoprotein by human monocytes.

Anna Tavridou1, Vangelis G Manolopoulos

  • 1Laboratory of Pharmacology, Medical School, Democritus University of Thrace, Alexandroupolis, Greece.

Pharmacology
|October 23, 2004
PubMed
Summary

HMG-CoA reductase inhibitors like atorvastatin and simvastatin reduce the uptake of modified LDL by monocytes. This suggests these statins may slow atherosclerosis progression by preventing foam cell formation.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Association of <i>ADIPOQ rs1501299</i> with long-COVID syndrome: a single-center cross-sectional study.

Annals of medicine·2026
Same author

Impact of Preservative-Free Travoprost on Intraocular Pressure and Ocular Surface in Primary Open-Angle Glaucoma Patients.

Life (Basel, Switzerland)·2025
Same author

Stimulating medicines repurposing in the EU: a pilot project.

Nature reviews. Drug discovery·2025
Same author

Elevated Troponin, D-Dimers and D-Dimers/Fibrinogen Ratio Increase Mortality Risk in Remdesivir-Treated COVID-19 Patients.

Journal of personalized medicine·2025
Same author

Pharmacotherapy of cardiovascular diseases from herbs and pills to nucleic acids.

European heart journal·2025
Same author

Direct Oral Anticoagulant-Related Bleeding in Atrial Fibrillation Patients Leads to <i>ADAMTS7</i> Promoter Demethylation.

Genes·2025

Area of Science:

  • Pharmacology
  • Cardiovascular Research
  • Cell Biology

Background:

  • Atherosclerosis involves modified low-density lipoprotein (LDL) uptake by monocytes.
  • HMG-CoA reductase inhibitors, calcium channel blockers, and ACE inhibitors are known for anti-atherogenic effects.
  • The specific impact of these drug classes on modified LDL uptake by monocytes requires further elucidation.

Purpose of the Study:

  • To investigate the effect of HMG-CoA reductase inhibitors, calcium channel blockers, and angiotensin-converting enzyme inhibitors on modified LDL uptake by U937 cells.
  • To determine if atorvastatin, simvastatin, calcium channel blockers, or ACE inhibitors influence a key event in atherosclerosis progression.

Main Methods:

  • U937 cells (human monocytic cell line) were treated with various drug classes.

Related Experiment Videos

  • Uptake of fluorescently labeled acetylated LDL by treated cells was quantified.
  • Flow cytometry was utilized to assess LDL uptake levels.

    • Main Results:

    • HMG-CoA reductase inhibitors, specifically atorvastatin and simvastatin (at 1-30 mumol/l), significantly inhibited modified LDL uptake by U937 cells.
    • Calcium channel blockers and angiotensin-converting enzyme inhibitors did not demonstrate an inhibitory effect on modified LDL uptake.
    • The inhibitory effect was observed for statins, suggesting a specific mechanism.

    Conclusions:

    • Atorvastatin and simvastatin may slow atherosclerosis progression.
    • These statins appear to exert their anti-atherogenic effect by inhibiting modified LDL uptake in monocytes.
    • This inhibition may prevent the formation of foam cells, a critical step in atherosclerotic plaque development.